Eisai sales and marketing update

Eisai launched Halaven eribulin in Russia to treat metastatic breast cancer in patients whose disease has progressed after at least two chemotherapy regimens. The company declined to disclose the price of the treatment. Halaven is a synthetic analog of halichondrin B. ...